Example: air traffic controller
2020 HCPCS Application Summary - CMS
Oct 01, 2020 · approved by the FDA under a Biologics License Application (BLA) on February 21, 2020 and is indicated for the preventive treatment of migraine in adults. VYEPTI (eptinezumab-jjmr) inhibits the activity of calcitonin gene-related peptide (CGRP), a neuropeptide known to play a key role in initiating and mediating migraine.
Download 2020 HCPCS Application Summary - CMS
Information
Domain:
Source:
Link to this page: